JP Morgan Chase’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

JP Morgan Chase’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-36,968	Closed	-$13K	–	5778
2017 Q3	$13K	Sell	36,968 -23,913	-39%	-$8.86K	﹤0.01%	4691
2017 Q2	$23K	Hold	60,881	–	–	﹤0.01%	4517
2017 Q1	$27K	Hold	60,881	–	–	﹤0.01%	4672
2016 Q4	$23K	Hold	60,881	–	–	﹤0.01%	4686
2016 Q3	$16K	Hold	60,881	–	–	﹤0.01%	4237
2016 Q2	$15K	Sell	60,881 -1,500	-2%	-$258	﹤0.01%	4284
2016 Q1	$7K	Sell	62,381 -34,170	-35%	-$3.7K	﹤0.01%	4331
2015 Q4	$11K	Hold	96,551	–	–	﹤0.01%	4201
2015 Q3	$18K	Buy	96,551 +9,439	+11%	+$3.21K	﹤0.01%	3841
2015 Q2	$61K	Buy	87,112 +37,311	+75%	+$25.8K	﹤0.01%	3907
2015 Q1	$33K	Buy	+49,801	New	+$34.8K	﹤0.01%	3962

Other funds holding GCVRZ

SCM

Stonehill Capital Management New York $350M AUM 73.6% 1-Year Est. Return

Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return

MCM

Mason Capital Management New York $607M AUM 1.77% 1-Year Est. Return

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Brigade Capital Management New York $1.26B AUM 194.27% 1-Year Est. Return

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

Whitebox Advisors Minneapolis, Minnesota $7.65B AUM 13.87% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

GCM

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

NGA

New Generation Advisors Manchester, Massachusetts $45.6M AUM 15.43% 1-Year Est. Return

JP Morgan Chase's GCVRZ Position: Q4 2017 in Review

JP Morgan Chase sold out of Sanofi Contingent Value Rights (GCVRZ) in Q4 2017, closing a stake of 36,968 shares — an estimated $13K sold.

JP Morgan Chase first reported a position in GCVRZ in Q1 2015 and held it in 11 quarters. The position peaked at $61K in Q2 2015. 105 funds tracked by Wall St. Rank hold GCVRZ as of Q4 2017.

JP Morgan Chase reported no remaining Sanofi Contingent Value Rights position as of Q4 2017 after selling out during the quarter.
JP Morgan Chase sold 36,968 Sanofi Contingent Value Rights shares in Q4 2017, an estimated $13K.
JP Morgan Chase first reported a position in Sanofi Contingent Value Rights in Q1 2015 and held it in 11 quarters.
JP Morgan Chase's Sanofi Contingent Value Rights position peaked at $61K in Q2 2015.
105 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q4 2017.

Based on JP Morgan Chase's 13F filing for Q4 2017, filed 13 Feb 2018.